Close

DLL1

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

DLL1 is a human homolog of the Notch Delta ligand and is a member of the delta/serrate/jagged family. It plays a role in mediating cell fate decisions during hematopoiesis. It may play a role in cell-to-cell communication. [provided by RefSeq, Jul 2008]
  • CAR Vector Products

  • Protein

Loading...
  • Target Species:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
XS-1222-ZP526 DLL1 (NOTCH1 Receptor) h(CD28-CD3ζ) Ligand-based CAR, pCDCAR1 Human DLL1-CD28-CD6ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-1222-ZP527 DLL1 (NOTCH2 Receptor) h(CD28-CD3ζ) Ligand-based CAR, pCDCAR1 Human DLL1-CD28-CD6ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-1222-ZP528 DLL1 (NOTCH3 Receptor) h(CD28-CD3ζ) Ligand-based CAR, pCDCAR1 Human DLL1-CD28-CD6ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-1222-ZP1926 DLL1 (NOTCH1 Receptor) h(41BB-CD3ζ) Ligand-based CAR, pCDCAR1 Human DLL1-41BB-CD6ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-1222-ZP1927 DLL1 (NOTCH2 Receptor) h(41BB-CD3ζ) Ligand-based CAR, pCDCAR1 Human DLL1-41BB-CD6ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-1222-ZP1928 DLL1 (NOTCH3 Receptor) h(41BB-CD3ζ) Ligand-based CAR, pCDCAR1 Human DLL1-41BB-CD6ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.